Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
-
Published:2022-07-27
Issue:1
Volume:13
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Wang Li, Kainulainen Markus H.ORCID, Jiang NannanORCID, Di Han, Bonenfant GastonORCID, Mills Lisa, Currier Michael, Shrivastava-Ranjan Punya, Calderon Brenda M., Sheth Mili, Mann Brian R., Hossain Jaber, Lin Xudong, Lester Sandra, Pusch Elizabeth A.ORCID, Jones Joyce, Cui Dan, Chatterjee Payel, Jenks M. Harley, Morantz Esther K., Larson Gloria P.ORCID, Hatta Masato, Harcourt Jennifer L., Tamin Azaibi, Li Yan, Tao Ying, Zhao Kun, Lacek KristineORCID, Burroughs Ashley, Wang WeiORCID, Wilson Malania, Wong Terianne, Park So Hee, Tong Suxiang, Barnes John R., Tenforde Mark W.ORCID, Self Wesley H., Shapiro Nathan I., Exline Matthew C., Files D. Clark, Gibbs Kevin W.ORCID, Hager David N., Patel Manish, Halpin Alison L., McMullan Laura K.ORCID, Lee Justin S., Xia HongjieORCID, Xie XupingORCID, Shi Pei-YongORCID, Davis C. Todd, Spiropoulou Christina F., Thornburg Natalie J.ORCID, Oberste M. Steven, Dugan Vivien G., Batra Dhwani, Beck Andrew S., Caravas Jason, Chau Reina, Cintron-Moret Roxana, Cook Peter W., Gerhart Jonathan, Gulvik Christopher A., Hassell Norman, Howard Dakota, Knipe Kristen, Kondor Rebecca J., Kovacs Nicholas A., Moser Kara, Reddy-Nagilla Roopa, Paden Clinton R., Rambo-Martin Benjamin, Mathew Sandra, Schmerer Matthew W., Shepard Samuel S., Shirk Philip, Stanton Richard A., Stark Thomas J., Sula Erisa, Tymeckia Kendall, Unoarumhi Yvette, Subbalakshmi Voleti, Zheng Xiao-yu, Wentworth David E.ORCID, Zhou BinORCID,
Abstract
AbstractThe evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence of new variant lineages that have exacerbated the COVID-19 pandemic. Some of those variants were designated as variants of concern/interest (VOC/VOI) by national or international authorities based on many factors including their potential impact on vaccine-mediated protection from disease. To ascertain and rank the risk of VOCs and VOIs, we analyze the ability of 14 variants (614G, Alpha, Beta, Gamma, Delta, Epsilon, Zeta, Eta, Theta, Iota, Kappa, Lambda, Mu, and Omicron) to escape from mRNA vaccine-induced antibodies. The variants show differential reductions in neutralization and replication by post-vaccination sera. Although the Omicron variant (BA.1, BA.1.1, and BA.2) shows the most escape from neutralization, sera collected after a third dose of vaccine (booster sera) retain moderate neutralizing activity against that variant. Therefore, vaccination remains an effective strategy during the COVID-19 pandemic.
Funder
U.S. Department of Health & Human Services | Centers for Disease Control and Prevention
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference32 articles.
1. Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020). 2. Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812–827.e819 (2020). 3. Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370, 1464–1468 (2020). 4. Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116–121 (2021). 5. Zhou, B. et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature 592, 122–127 (2021).
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|